
WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

MARCH 20, 2018

[Vividion Therapeutics](#), a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive \$101 million in upfront and equity consideration. The multi-year collaboration will focus on the identification and development of small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit, against targets for a range of oncology, neurodegenerative and inflammatory indications.

The WilmerHale deal team counseling Vividion included [Steven Singer](#), [Steven Barrett](#) and [Mat Trachok](#).

[Read Vividion Therapeutics' press release](#) for more information.